Prof Tom John
@drtomjohn.bsky.social
Thoracic medical oncologist Peter Mac All expressed views are my own Musician (mayhemtom) - debut album now on Spotify Mayhemtom.com.au linktr.ee/mayhemtom
Proud to be part of this new podcast series with @DrAlexAdjei, where we provide insights into some of the key papers from @JTOonline. JTO Insights: April 2026 jto.org/audio-do/jto-i… @IASLC Available on all streaming platforms:podcasts.apple.com/au/podcast/j...91open.spotify.com/episode/3NYf...lg
JTO Insights: April 2026
Podcast Episode · JTO Insights · 16 April · 29min
podcasts.apple.com
Happy to share this paper from one of our #Swiss residents @PeterMacCC: Does IO given in #SCLC up front impact responses and survival in subsequent lines of therapy? Sadly the answer was no, chemo outcomes were similar to that seen pre-IO. Maybe BiTES? authors.elsevier.com/c/1lw8qcYZOi...
authors.elsevier.com
Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025
So much fun rehearsing some acoustic tunes with @drsanjaypopat.bsky.social - don’t forget to stick around after the #WCLC25 plenary tomorrow evening @iaslc.bsky.social
Looking forward to playing some tunes with my good friend and musician @drsanjaypopat.bsky.social tomorrow at #WCLC25. Make sure you stick around at the welcome reception Saturday evening!
Loving this @mayhemtomi track, a lovely collaboration with @dean_fennell on synths. Inspired by the “Pale blue dot speech” from Carl Sagan. Check it out on all streaming platforms details here: mayhemtom.com.au
Melbourne Oncologist-Turned-Musician: Songs of Love, Burnout, and Grief
Discover the moving music of a Melbourne oncologist who channels experiences of love, burnout, and grief into powerful songs. A unique journey from the world of medicine to creating heartfelt, soulful...
mayhemtom.com.au
🙏🏽 ABC for shining the light on 🇦🇺 deadliest cancer. Bring on #lungcancer screening www.abc.net.au/news/2025-06... @abcnewsbot.bsky.social @gerryhanna.bsky.social @drtomjohn.bsky.social @dkarikios.bsky.social @bensolomon1.bsky.social
Australia's deadliest cancer to get new screening program
After years of lobbying from patients, the first ever national lung cancer screening program will roll out next month for people who have a significant history of smoking.
abc.net.au
🇦🇺 guidelines for #lungcancer screening. Screening coming 1st July. Great step forward in #lungcancer Mx. Spread the word. www.health.gov.au/our-work/nlc... @newsgp.bsky.social @ausgov.bsky.social @drtomjohn.bsky.social @bensolomon1.bsky.social @dkarikios.bsky.social
health.gov.au
If you’re interested in where #lungcancer vaccines are at relative to #melanoma, check out this @togaanz.bsky.social podcast with @gvlongphdmd.bsky.social and Ken OByrne. podcasts.apple.com/au/podcast/v... open.spotify.com/episode/0OJb...
Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy
Conversations in Lung Cancer Research · Episode
open.spotify.com
Australia completely lacks a dedicated training program for clinician scientists. With the vision and support of VMIAL @petermaccc.bsky.social is extremely proud to announce the first clinician-scientist fellowship. If you meet the eligibility criteria PLEASE APPLY! www.nature.com/naturecareer...
Clinician Scientist Fellowship - Parkville, Melbourne (AU) job with Peter MacCallum Cancer Centre – Parkville | 12839522
Peter Mac is launching Australia’s first clinician-scientist fellowship to advance cancer care, fostering innovation and global collaboration.
nature.com
Close to releasing first single from new album. If you’re interested please presave it. Presaves help the #spotifyaunz and #applemusic algorithm figure out how hot a #indie #indiemusic track might be. gyro.to/Atheistic
Atheistic
Listen to content by Mayhemtom.
gyro.to
🔥 @natmedicine.bsky.social 🆙 ✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC 🎯MRD preceded imaging DFS by a median of 4.7 🩸RaDaR MRD analysis 👥 Dr. Roy Herbst @drtomjohn.bsky.social #LCSM @oncoalert.bsky.social www.nature.com/articles/s41...
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...
nature.com
Prof Tom John@drtomjohn.bsky.social · last yr.Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...
nature.com
Great day for lung cancer care!. Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! Just a press release for now but full data upcoming! #lcsm news.bms.com/news/corpora...
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survi...
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo ® (nivolumab) in combination with platinum-do...
news.bms.com
Non KRAS G12C mutations an important unmet need in lung cancer: we see them often, including in non-smokers Nice work here highlighted by @drtomjohn.bsky.social We hope to open 1L RMC-6236 trial at Chelsea & Westminster later this year
Prof Tom John@drtomjohn.bsky.social · 2y agoCongratulations to Adel from @petermac for this analysis showing KRAS G12D patients are more likely to be non-smokers but also associated with low PDL1, comutations with TP53/STK11 and derive limited immunotherapy response. Area of need for targeted Rx #LCSM smex-ctp.trendmicro.com/wis/clicktim...
Congratulations to Adel from @petermac for this analysis showing KRAS G12D patients are more likely to be non-smokers but also associated with low PDL1, comutations with TP53/STK11 and derive limited immunotherapy response. Area of need for targeted Rx #LCSM smex-ctp.trendmicro.com/wis/clicktim...
smex-ctp.trendmicro.com
*New Publication* led by Dr Adel Shahnam from @petermaccc.bsky.social in Lung Cancer Poorer survival outcomes in patients with KRAS G12D mutations receiving immunotherapy. Novel targeted therapies should be examined in detail for this population. www.lungcancerjournal.info/article/S016... #lcsm
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
The Kirsten rat sarcoma oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small-cell lung cancer (NSCLC), occurring in approximately 30 % of cases [1]. KRAS mutations are ...
lungcancerjournal.info
www.theguardian.com/commentisfre...
We are seeing anti-medical, anti-science narratives everywhere – how can doctors like me respond? | Mariam Tokhi
Medical practitioners are no longer trusted instinctively, with sometimes devastating consequences. How do we engage with people who mistrust us?
theguardian.com
HIT IT WITH YOUR BEST SHOT 👊 Catch our latest podcast on IO in early-stage NSCLC in the Australian context. Apple: https://buff.ly/3ZgBePP Spotify: https://buff.ly/3Ze0I0c
Lung cancer is the leading cause of cancer death in women. Don't ignore the signs! Thanks for coming on the journey with us this #LungCancerAwarenessMonth Find out more > https://buff.ly/3YG2OWB #LCAM
Time is running out to join us for the Kosi Climb with Prof Nick Pavlakis! Together, we can make an impact. Don't miss your chance to make a difference and be part of something special! Registrations close soon. Find out more > https://buff.ly/3Tov4LA
Having trouble thinking of a Christmas gift for someone? Go to ChatGPT and type in a summary of the person, a price range, and ask for gift ideas. List (with links) will follow. Tell others to do this for the gifts you will receive. Let’s (let AI) raise the standard of gift giving this Xmas!
Excellent summary from @donnadlubsky.social I really think we should be taxing these industries more. The amount of money wasted on supplements could be used to help fund trials and treatments that are proven to work. www.theguardian.com/commentisfre...
Multivitamins promise glowing skin, better sleep and a longer life. But who do supplements really benefit? | Donna Lu
For healthy people, pills, patches and gummies just create ‘expensive urine’. But for those with nutrient deficiencies, vitamin supplements have clear benefits
theguardian.com
With every new #lungcancer research finding, we move the needle for those impacted. It's why Dr @gerryhanna.bsky.social believes that LC research is improving care for patients in real time – we’re shifting the dial! Let's continue this. #BecauseofResearch #LCAM @younglungcancer.bsky.social
Always wonderful to be part of the #TOGAPreceptorship going through the main papers that determine how we treat #NSCLC today. Excellent presentations and discussions. But the best part is catching up with good mates! The future of thoracic oncology is bright 🌟
@oncoalert.bsky.social Starter pack Easy 👉🏼one click & followed all go.bsky.app/GKXp9Fy
#LungCancer survival rates rose 22% from 2015 to 2019. While promising, we want to see those numbers go much higher…while we're at it, let's shoot for 10, 15, 20 or more years. Learn how you can make an impact this Lung Cancer Awareness Month: buff.ly/4eDVXTo. #LCAM2024
